effects of lishen injection on serum estradiol(e2), testosterone(t) and the e2/t ratio in 30 cases of postmenopausal patients with coronary heart disease and of kidney deficiency type were observed.
it is also approved for use in combination with an aromatase inhibitor for the treatment of postmenopausal patients with her2 and hormone receptor co-positive metastatic breast cancer.